Investing in the New Future of Cancer Therapy
TILT Biotherapeutics is the world’s leading company developing investigational adenoviral immunotherapy platform for solid tumor cancers. With an ongoing group-wide reorganization of its operations, TILT Biotherapeutics Oy becomes a holding company and offers distinct investment opportunities for newly formed fully owned spin-out companies.
Funding
TILT Biotherapeutics was formed in 2013 and has secured more than 70 M€ of funding (about 75% from equity and the rest in non-dilutive funding) from investors that include:
- European Innovation Council (EIC Fund)
- Lifeline Ventures
- Finnish Industry Investment Ltd (Tesi)
- Stephen Industries Inc Ltd.
- Growth investment firm Springvest Oyj and Finnish private investors
- Business Finland
- U.S. Department of Defence
The latest equity investment round was completed in March 2025.